- Home
- SCWO vs NRXP Comparison
SCWO vs NRXP Comparison
Compare SCWO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCWO | NRXP |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 54.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCWO | NRXP |
|---|---|---|
| Price | $2.87 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 55.9K | ★ 754.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $215,037.00 | N/A |
| Revenue This Year | $5,945.19 | $9,292.65 |
| Revenue Next Year | $106.82 | $376.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $1.58 |
| 52 Week High | $3.60 | $3.84 |
Technical Indicators
Market Signals| Indicator | SCWO | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 57.45 |
| Support Level | $2.35 | $1.98 |
| Resistance Level | $2.97 | $2.23 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 37.17 | 62.34 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.